ADCT
ADC Therapeutics·NYSE
--
--(--)
--
--(--)
ADCT fundamentals
During Q4 2025, ADC Therapeutics (ADCT) reported revenue of 23.06M, a YoY change of 36.36%. Net income was -6.41M, a YoY change of 79.14%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 1.96M -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 3.76M -- | 13.15M -- | 17.01M -- | 46.50M -- | 17.29M +359.87% | 76.32M +480.52% | 69.80M +310.34% | 18.99M -59.16% | 19.28M +11.52% | 14.49M -81.01% | 16.79M -75.94% | 18.05M -4.94% | 17.41M -9.71% | 18.46M +27.40% | 16.91M +0.71% | 23.03M +27.59% | 18.84M +8.21% | 16.43M -11.03% | 23.06M +36.36% | 81.36M -- |
Sales and Services Revenue | 1.96M -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 3.76M -- | 13.15M -- | 17.01M -- | 46.50M -- | 17.29M +359.87% | 76.32M +480.52% | 69.80M +310.34% | 18.99M -59.16% | 19.28M +11.52% | 14.49M -81.01% | 16.79M -75.94% | 18.05M -4.94% | 17.41M -9.71% | 18.46M +27.40% | 16.91M +0.71% | 23.03M +27.59% | 18.84M +8.21% | 16.43M -11.03% | 23.06M +36.36% | 81.36M -- |
Cost of Revenue | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 121.00K -- | 502.00K -- | 770.00K -- | 529.00K -- | 2.27M +1772.73% | 1.29M +157.97% | -789.00K -202.47% | -27.00K -105.10% | 1.13M -50.04% | 208.00K -83.94% | 1.22M +254.12% | 2.51M +9396.30% | 1.22M +7.51% | 851.00K +309.13% | 1.37M +12.75% | 2.06M -17.89% | 836.00K -31.31% | 1.20M +41.25% | 1.70M +23.92% | 5.80M -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 1.39M -- | -- -- | -- -- | -- -- | 4.58M +228.72% | -27.00K -- | 1.13M -- | 208.00K -- | 1.22M -73.44% | 2.51M +9396.30% | 1.22M +7.51% | 851.00K +309.13% | 1.37M +12.75% | 2.06M -17.89% | 836.00K -31.31% | 1.20M +41.25% | 1.70M +23.92% | 5.80M -- |
Gross Profit | 1.96M -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 3.64M -- | 12.64M -- | 16.24M -- | 45.97M -- | 15.03M +312.89% | 75.03M +493.33% | 69.31M +326.78% | 19.02M -58.63% | 18.15M +20.81% | 14.29M -80.96% | 15.57M -77.53% | 15.54M -18.28% | 16.19M -10.79% | 17.61M +23.30% | 15.54M -0.22% | 20.97M +34.93% | 18.00M +11.18% | 15.22M -13.56% | 21.36M +37.45% | 75.56M -- |
Operating Expenses | 25.85M -- | 43.88M -- | 44.95M +73.89% | 52.43M -- | 78.00M -- | 70.67M +61.02% | 74.12M +64.90% | 70.44M +34.35% | 79.02M +1.31% | 86.33M +22.17% | 84.44M +13.92% | 78.14M +10.94% | 80.05M +1.30% | 69.23M -19.81% | 57.80M -31.55% | 50.43M -35.46% | 55.55M -30.60% | 49.16M -29.00% | 45.23M -21.74% | 53.18M +5.44% | 47.98M -13.64% | 49.44M +0.57% | 62.15M +37.40% | 46.19M -13.13% | 39.28M -18.13% | 197.06M -- |
Selling, General and Administrative Expenses | 4.09M -- | 8.51M -- | 19.00M +364.64% | 20.27M -- | 29.45M -- | 31.49M +270.07% | 34.59M +82.05% | 33.63M +65.90% | 36.53M +24.04% | 37.38M +18.70% | 35.90M +3.79% | 36.46M +8.42% | 31.31M -14.28% | 30.85M -17.46% | 26.46M -26.30% | 23.35M -35.95% | 25.22M -19.45% | 23.42M -24.09% | 20.94M -20.86% | 20.68M -11.47% | 20.87M -17.24% | 20.51M -12.44% | 18.97M -9.41% | 19.01M -8.03% | 21.44M +2.72% | 79.93M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | 22.10M -- | -- -- | -- -- | -- -- | 64.78M +193.11% | -- -- | -- -- | -- -- | 69.05M +6.59% | 15.35M -- | 14.46M -- | 13.73M -- | 13.93M -79.83% | 11.39M -25.80% | 10.70M -25.98% | 10.67M -22.27% | 11.25M -19.21% | 10.55M -7.35% | 10.15M -5.18% | 10.69M +0.14% | 11.99M +6.53% | 43.37M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | 55.13M -- | -- -- | -- -- | -- -- | 71.46M +29.62% | -- -- | -- -- | -- -- | 72.01M +0.76% | 15.50M -- | 12.00M -- | 9.62M -- | 11.29M -84.31% | 12.03M -22.40% | 10.24M -14.70% | 10.00M +3.93% | 9.62M -14.80% | 9.96M -17.26% | 8.82M -13.83% | 8.33M -16.76% | 9.46M -1.74% | 36.56M -- |
Research and Development Expenses | 21.76M -- | 35.38M -- | 25.95M +19.26% | 32.16M -- | 48.55M -- | 39.17M +10.73% | 39.53M +52.34% | 36.80M +14.46% | 42.49M -12.48% | 48.95M +24.97% | 48.54M +22.78% | 41.68M +13.23% | 48.73M +14.69% | 38.38M -21.61% | 31.34M -35.43% | 27.08M -35.02% | 30.33M -37.76% | 25.73M -32.94% | 24.30M -22.48% | 32.50M +20.02% | 27.10M -10.65% | 28.93M +12.41% | 30.09M +23.85% | 26.80M -17.53% | 18.18M -32.90% | 104.00M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | 6.41M -- | 377.00K -- | -7.71M -- | -- -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 6.68M -- | -- -- | 7.37M -- | -- -- |
Operating Income | -23.89M -- | -43.88M -- | -44.95M -88.17% | -52.43M -- | -78.00M -- | -70.67M -61.02% | -70.48M -56.80% | -57.79M -10.23% | -62.78M +19.51% | -40.36M +42.88% | -69.41M +1.52% | -3.11M +94.61% | -10.74M +82.90% | -50.21M -24.39% | -39.65M +42.88% | -36.15M -1060.85% | -39.98M -272.30% | -33.61M +33.06% | -29.04M +26.75% | -35.56M +1.62% | -32.44M +18.87% | -28.46M +15.32% | -44.15M -52.02% | -30.97M +12.92% | -17.92M +44.76% | -121.50M -- |
Non-Operating Income (Loss) | 633.00K -- | 509.00K -- | -81.50M -12975.83% | 32.10M -- | 22.20M -- | 19.25M +3680.94% | -1.85M +97.73% | -13.61M -142.41% | 6.43M -71.04% | 22.53M +17.08% | 4.09M +321.44% | -48.20M -254.14% | -9.45M -247.02% | -8.65M -138.37% | -13.77M -436.70% | -10.66M +77.88% | -1.88M +80.09% | -12.83M -48.39% | -7.27M +47.22% | -8.31M +22.01% | 1.39M +173.75% | -9.97M +22.27% | -11.24M -54.70% | -10.00M -20.23% | 11.11M +700.14% | -20.11M -- |
Income (Loss) from Affiliates | -- -- | -- -- | -- -- | -- -- | 24.37M -- | -- -- | -- -- | -- -- | -6.67M -127.38% | -- -- | -- -- | -- -- | -10.08M -51.14% | -1.36M -- | -767.00K -- | -1.41M -- | -1.99M +80.28% | -687.00K +49.60% | -597.00K +22.16% | -260.00K +81.55% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 -- | -- -- |
Income (Loss) from Joint ventures | -- -- | -- -- | -- -- | -- -- | 24.37M -- | -- -- | -- -- | -- -- | -6.67M -127.38% | -- -- | -- -- | -- -- | -10.08M -51.14% | -1.36M -- | -767.00K -- | -1.41M -- | -1.99M +80.28% | -687.00K +49.60% | -597.00K +22.16% | -260.00K +81.55% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 -- | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -45.41M -- | -- -- | -- -- | -- -- | 34.89M +176.84% | -- -- | -- -- | -- -- | 40.12M +14.97% | 616.00K -- | 20.00K -- | 140.00K -- | -279.00K -100.70% | -3.07M -598.05% | 2.23M +11050.00% | -- -- | 296.00K +206.09% | 0 +100.00% | 0 -100.00% | -- -- | 0 -100.00% | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -576.00K -- | -- -- | -- -- | -- -- | 50.00K +108.68% | -- -- | -- -- | -- -- | -110.00K -320.00% | -52.00K -- | 15.00K -- | 39.00K -- | -54.00K +50.91% | -37.00K +28.85% | -59.00K -493.33% | -- -- | -80.00K -48.15% | -90.00K -143.24% | -847.00K -1335.59% | -- -- | -670.00K -737.50% | -- -- |
Other Non-Operating Income (Loss) | 10.00K -- | 177.00K -- | -80.80M -808120.00% | 33.87M -- | 45.76M -- | 21.23M +11894.35% | 693.00K +100.86% | -9.36M -127.64% | -12.34M -126.97% | 13.44M -36.68% | 12.88M +1757.86% | -37.12M -296.48% | -31.20M -152.77% | 269.00K -98.00% | -5.10M -139.63% | 681.00K +101.83% | 10.06M +132.24% | 510.00K +89.59% | 583.00K +111.43% | 1.62M +138.47% | 10.46M +3.97% | 293.00K -42.55% | 665.00K +14.07% | 925.00K -43.04% | 22.44M +114.55% | 24.32M -- |
Net Interest Expense | -623.00K -- | -332.00K -- | 702.00K +212.68% | 1.78M -- | 1.95M -- | 1.99M +697.89% | 2.54M +261.82% | 4.25M +139.11% | 9.50M +387.93% | -9.09M -557.98% | 8.79M +245.87% | 11.08M +160.84% | 8.18M -13.93% | 8.12M +189.28% | 7.94M -9.65% | 10.11M -8.75% | 9.62M +17.63% | 9.55M +17.64% | 9.43M +18.76% | 9.68M -4.29% | 9.29M -3.46% | 10.18M +6.58% | 11.06M +17.37% | 10.92M +12.84% | 10.66M +14.82% | 42.82M -- |
Interest Expense | 36.00K -- | 42.00K -- | 897.00K +2391.67% | 1.94M -- | 2.05M -- | 2.00M +4661.90% | 2.56M +184.84% | 4.26M +119.85% | 9.52M +365.07% | 9.22M +360.85% | 8.80M +244.46% | 11.36M +166.26% | 7.55M -20.69% | 10.29M +11.65% | 10.31M +17.13% | 12.82M +12.86% | 12.91M +70.98% | 12.50M +21.43% | 12.68M +22.99% | 13.12M +2.35% | 11.92M -7.67% | 12.23M -2.13% | 13.00M +2.51% | 13.39M +2.10% | 13.01M +9.19% | 51.63M -- |
Interest Income | 659.00K -- | 374.00K -- | 195.00K -70.41% | 163.00K -- | 100.00K -- | 15.00K -95.99% | 15.00K -92.31% | 16.00K -90.18% | 20.00K -80.00% | 18.31M +121953.33% | 16.00K +6.67% | 273.00K +1606.25% | -627.00K -3235.00% | 2.17M -88.12% | 2.37M +14725.00% | 2.70M +890.11% | 3.29M +624.72% | 2.95M +35.54% | 3.25M +37.14% | 3.44M +27.19% | 2.63M -19.97% | 2.05M -30.33% | 1.93M -40.55% | 2.47M -28.16% | 2.35M -10.67% | 8.81M -- |
Pretax Income From Continuing Operations | -23.25M -- | -43.38M -- | -126.45M -443.79% | -20.33M -- | -55.80M -- | -51.42M -18.54% | -72.33M +42.80% | -71.40M -251.21% | -56.35M -0.98% | -17.83M +65.32% | -65.32M +9.69% | -51.32M +28.13% | -22.43M +60.20% | -58.86M -230.08% | -53.42M +18.22% | -46.81M +8.78% | -41.86M -86.63% | -46.44M +21.09% | -36.31M +32.03% | -43.88M +6.26% | -31.05M +25.83% | -38.44M +17.24% | -55.39M -52.55% | -40.97M +6.64% | -6.81M +78.06% | -141.61M -- |
Income Tax Expense | 94.00K -- | 100.00K -- | 104.00K +10.64% | -3.00K -- | 126.00K -- | 107.00K +7.00% | 240.00K +130.77% | 145.00K +4933.33% | -21.97M -17537.30% | -1.17M -1193.46% | -947.00K -494.58% | -711.00K -590.34% | 3.06M +113.90% | 518.00K +144.27% | -4.50M -374.97% | -85.00K +88.05% | 43.17M +1313.13% | 163.00K -68.53% | 234.00K +105.20% | 90.00K +205.88% | -321.00K -100.74% | 165.00K +1.23% | 1.25M +435.90% | 0 -100.00% | -404.00K -25.86% | 1.01M -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | 327.00K -- | -- -- | -- -- | -- -- | 4.57M +1297.55% | -- -- | -- -- | -- -- | 1.85M -59.58% | -- -- | -- -- | -- -- | 2.00M +8.39% | -- -- | -- -- | -- -- | 166.00K -91.71% | -- -- | -- -- | -- -- | 1.01M +511.45% | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -26.05M -- | -- -- | -- -- | -- -- | -708.00K +97.28% | -- -- | -- -- | -- -- | 37.10M +5340.68% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -23.35M -- | -43.48M -- | -126.56M -442.05% | -20.33M -- | -55.93M -- | -51.53M -18.52% | -72.57M +42.66% | -71.55M -251.97% | -34.38M +38.53% | -16.66M +67.67% | -64.37M +11.29% | -50.61M +29.27% | -25.48M +25.87% | -59.37M -256.37% | -48.92M +24.00% | -46.73M +7.67% | -85.03M -233.65% | -46.61M +21.50% | -36.54M +25.30% | -43.97M +5.90% | -30.73M +63.86% | -38.60M +17.17% | -56.65M -55.01% | -40.97M +6.83% | -6.41M +79.14% | -142.62M -- |
Net Income Attributable to Owners of the Company | -23.35M -- | -43.48M -- | -126.56M -442.05% | -20.33M -- | -55.93M -- | -51.53M -18.52% | -72.57M +42.66% | -71.55M -251.97% | -34.38M +38.53% | -16.66M +67.67% | -64.37M +11.29% | -50.61M +29.27% | -24.16M +29.74% | -59.37M -256.37% | -48.92M +24.00% | -46.73M +7.67% | -85.03M -251.99% | -46.61M +21.50% | -36.54M +25.30% | -43.97M +5.90% | -30.73M +63.86% | -38.60M +17.17% | -56.65M -55.01% | -40.97M +6.83% | -6.41M +79.14% | -142.62M -- |
Net Income Attributable to Common Stockholders | -23.35M -- | -43.48M -- | -126.56M -442.05% | -20.33M -- | -55.93M -- | -51.53M -18.52% | -72.57M +42.66% | -71.55M -251.97% | -34.38M +38.53% | -16.66M +67.67% | -64.37M +11.29% | -50.61M +29.27% | -24.16M +29.74% | -59.37M -256.37% | -48.92M +24.00% | -46.73M +7.67% | -85.03M -251.99% | -46.61M +21.50% | -36.54M +25.30% | -43.97M +5.90% | -30.73M +63.86% | -38.60M +17.17% | -56.65M -55.01% | -40.97M +6.83% | -6.41M +79.14% | -142.62M -- |
Other Comprehensive Income | -58.00K -- | -202.00K -- | -13.00K +77.59% | 151.00K -- | -65.00K -- | 36.00K +117.82% | 20.00K +253.85% | -140.00K -192.72% | -- -- | -158.00K -538.89% | 3.23M +16075.00% | -484.00K -245.71% | 984.00K -- | -154.00K +2.53% | -314.00K -109.71% | -256.00K +47.11% | -1.19M -221.14% | -108.00K +29.87% | -137.00K +56.37% | 541.00K +311.33% | -1.63M -36.58% | 329.00K +404.63% | 704.00K +613.87% | -314.00K -158.04% | 185.00K +111.36% | 904.00K -- |
Total Comprehensive Income | -23.41M -- | -43.68M -- | -126.57M -440.76% | -20.18M -- | -55.99M -- | -51.49M -17.89% | -72.55M +42.68% | -71.69M -255.30% | -- -- | -16.82M +67.34% | -61.14M +15.73% | -51.09M +28.73% | -24.50M -- | -59.53M -253.93% | -49.24M +19.47% | -46.98M +8.04% | -86.22M -251.92% | -46.71M +21.53% | -36.68M +25.50% | -43.43M +7.56% | -32.35M +62.48% | -38.27M +18.07% | -55.94M -52.51% | -41.28M +4.95% | -6.22M +80.76% | -141.72M -- |
Total Comprehensive Income Attributable to Owners of the Company | -23.41M -- | -43.68M -- | -126.57M -440.76% | -20.18M -- | -55.99M -- | -51.49M -17.89% | -72.55M +42.68% | -71.69M -255.30% | -34.95M +37.59% | -16.82M +67.34% | -61.14M +15.73% | -51.09M +28.73% | -23.57M +32.54% | -59.53M -253.93% | -49.24M +19.47% | -46.98M +8.04% | -86.22M -265.75% | -46.71M +21.53% | -36.68M +25.50% | -43.43M +7.56% | -32.35M +62.48% | -38.27M +18.07% | -55.94M -52.51% | -41.28M +4.95% | -6.22M +80.76% | -141.72M -- |
Basic EPS | -0.49 -- | -0.85 -- | -2.01 -310.20% | -0.29 -- | -0.73 -- | -0.67 +21.18% | -0.95 +52.74% | -0.93 -220.69% | -0.45 +38.36% | -0.22 +67.16% | -0.84 +11.58% | -0.65 +30.11% | -0.32 +28.89% | -0.73 -231.82% | -0.6 +28.57% | -0.57 +12.31% | -1.03 -221.88% | -0.56 +23.29% | -0.38 +36.67% | -0.42 +26.32% | -0.31 +69.90% | -0.36 +35.71% | -0.5 -31.58% | -0.3 +28.57% | -0.05 +83.87% | -1.21 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.73 -- | -0.6 -- | -0.57 -- | -- -- | -0.56 +23.29% | -0.38 +36.67% | -0.42 +26.32% | -- -- | -0.36 +35.71% | -0.5 -31.58% | -0.3 +28.57% | -- -- | -- -- |
Diluted EPS | -0.49 -- | -0.85 -- | -2.01 -310.20% | -0.29 -- | -- -- | -0.67 +21.18% | -0.95 +52.74% | -0.93 -220.69% | -0.45 -- | -0.22 +67.16% | -0.84 +11.58% | -0.65 +30.11% | -- -- | -0.73 -231.82% | -0.6 +28.57% | -0.57 +12.31% | -- -- | -0.56 +23.29% | -0.38 +36.67% | -0.42 +26.32% | -- -- | -0.36 +35.71% | -0.5 -31.58% | -0.3 +28.57% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.73 -- | -0.6 -- | -0.57 -- | -- -- | -0.56 +23.29% | -0.38 +36.67% | -0.42 +26.32% | -- -- | -0.36 +35.71% | -0.5 -31.58% | -0.3 +28.57% | -- -- | -- -- |
You can ask Aime
Did ADC Therapeutics beat or miss consensus estimates last quarter?What guidance did ADC Therapeutics's management provide for the next earnings period?What is ADC Therapeutics's gross profit margin?What is the revenue and EPS growth rate for ADC Therapeutics year over year?What does ADC Therapeutics do and what are its main business segments?What is ADC Therapeutics's latest dividend and current dividend yield?What were the key takeaways from ADC Therapeutics’s earnings call?What is the market's earnings forecast for ADC Therapeutics next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
